China’s First Gene Therapy for Deafness, RRG-003, Begins Clinical Study
RRG-003, an adeno-associated virus (AAV) gene therapy co-developed by China’s Shanghai Dingxin Gene Technology Co.,...
Clinical trial approval / initiation
Legend Biotech Receives IND Approval for LB2102 CAR-T Therapy
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced receiving Investigational New Drug (IND) approval for...
Sun-Novo Pharma Gains NMPA Approval for STC007 Clinical Study in CKD-aP
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced receiving approval from the...
Mabwell Receives Approval for Clinical Study of 9MW3011 in Polycythemia Vera
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced receiving approval to conduct a...
Henlius’ Serplulimab Phase III Study Approved in Spain for LS-SCLC
China-based Shanghai Henlius Biotech (HKG: 2696) has announced that its global, multi-center Phase III clinical...
Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Three New Drugs
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clinical trial approvals for three in-house...
Haisco’s HSK31858 Gains Ethical Approval for Phase II Study in NCFBE
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its drug candidate HSK31858...
Ascletis Pharma’s PD-L1 Inhibitor ASC61 Gains NMPA IND Approval
China-based Ascletis Pharma Inc. (HKG: 1672) has announced the approval of the Investigational New Drug...
Kelun Pharma’s SKB264 Advances to Phase II Study for NSCLC
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its antibody drug conjugate...
Kanghong Pharma Gains NMPA Approval for Innovative Eye Injection KH631
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving clinical trial approvals...
Kelun-Biotech’s SKB264 Receives FDA Approval for Phase II Study
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the US FDA to...
LaNova Medicines Gets NMPA Approval for LM-305 Clinical Study
Shanghai-based cancer therapy developer LaNova Medicines Ltd has announced that it has received approval from...
Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity
China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first patient dosing in the randomized,...
Guangdong Zhongsheng Starts Phase III Trial for COVID-19 Drug RAY1216
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the enrollment of the first...
FDA Approves Phase Ib Study for Jiangsu Yahong’s APL1401 in Ulcerative Colitis
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced that...
CanSino Biologics’ Inhalable COVID-19 Vaccine Authorized in Morocco
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received emergency use...
Sinocelltech’s SCTV01E Vaccine Receives NMPA Approval for Phase II Study
China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received approval from the...
LianBio Initiates Phase I Study of SHP2 Inhibitor BBP-398 in China
Sino-US biotech LianBio has announced the first patient dosing in a Phase I clinical study...
Ascentage Pharma Gains CDE Approval for Phase I Study of APG-5918
Suzhou-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the Center...
Liaoning Chengda’s ACYW135 Meningococcal Vaccine Receives NMPA Clearance
China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) has announced that it has received clinical...